AiXin Life International, Inc. Company Summary

Business Focus

AiXin Life International, Inc. is a Colorado holding company with operations primarily conducted in China through its subsidiaries. Its core business activities involve providing health and wellness products to the growing middle class in China.

Products and Services

• Develops, manufactures, markets, and sells:
  • Healthcare and nutritional products including:
    • Herbs and greens
    • Traditional Chinese remedies
    • Functional foods such as weight management, probiotics, and drinks
  • Distributes products of third-party clients for marketing services
• Utilizes a diversified omni-channel sales model including:
  • Retail and wholesale product sales
  • Company-owned pharmacies
  • Direct marketing through sales teams
  • Online sales channels
• Operating through a subsidiary, AiXinZhonghong, which employs direct marketing teams that organize large-scale entertainment-style events and online activities to promote products.
• Owns and operates a chain of pharmacies (8 locations).
• Engages in research, development, manufacturing, and wholesale distribution of health and wellness products via Yunnan Runcangsheng, which operates a large 13,000 square meter production facility, with R&D centers, extraction, and processing workshops.

Key Operations & Assets

• Pharmacies: Operate at 8 locations in Chengdu, distributing health and wellness products and serving as customer education centers.
• Manufacturing: Runcangsheng, with a 13,000 sqm facility, produces traditional Chinese medicines, extracts, capsules, tablets, and functional foods.
• Product Portfolio includes: Rhinos king, colostrum powder, ganmaoling granules, antibiotics (amoxicillin, loratadine), traditional Chinese remedies, and health foods designed for ailments like hypertension and obesity.

Business Strategy

• Build recognized, premium health and wellness brands with proprietary and third-party products.
• Focus on product development and innovation, including ingredient cultivation, testing, and new product formulation.
• Create a differentiated, personalized customer experience via trained staff, loyalty programs, educational seminars, and multichannel engagement.
• Expand through acquisitions of pharmacies, retail outlets, nursing homes, clinics, and new product lines.
• Maintain a vertical integration model to respond rapidly to consumer trends and feedback.

Financial Highlights

• Revenue (2024): Approximately $3.82 million, decreased 6% from $4.09 million in 2023.
  • Product sales (2024): $3.24 million (up 12% from 2023)
  • Direct sales: $504,097 (down 57% from 2023)
  • Pharmacies: $822,958 (down 12% from 2023)
  • Hotel: $585,634 (down 51% from 2023)
  • Runcangsheng sales: $1.91 million (up 139% from 2023, 50% of total revenue)
• Net Loss (2024): Approximately $2.77 million, which increased from a loss of $2.09 million in 2023.
• Employees: About 120 employees as of April 1, 2025.
• Market Capitalization (mid-2024): Estimated at $5.65 million based on 16,419,012 shares at the reported share price of $0.659.
• Outstanding Shares (May 5, 2025): 24,999,834 shares of common stock.

Recent Developments & Assets

• Acquired 9 pharmacies in Chengdu (2021), now operating 8.
• Acquired Yunnan Runcangsheng in September 2022, establishing a vertically integrated platform for research, production, and distribution of health products.
• Leased a new hotel property in Chengdu (2024) with an 18,000 sqm facility, replacing a terminated lease on another hotel.
• Engaged in ongoing expansion ambitions including healthcare product lines, retail outlets, and healthcare facilities.

Key Management

• Quanzhong Lin: Chairman, President, CEO — owning 58% of outstanding shares.
• Other directors and officers: Include Yao-Te Wang, Xinliang Li (Christopher Lee), Huiliang Jiao, and Xiaowen Zheng, with various roles in management and finance.

Employees & Operations

• Employees: ~120
• Key assets: Manufacturing facility, chain of pharmacies, hotel property, online marketing platform, research centers.

Revenue & Operating Losses

• Operating costs exceed revenues, leading to net losses.
• The company anticipates continued losses and cash flow tightness, with liquidity challenges due to a working capital deficit.

This summary reflects the company's business lines, strategic focus, operational assets, financial performance, and management structure based solely on provided information.